Press Releases

GKC names John Schellhorn new President and CEO - 5 October 2017

GKC announced today that it has appointed John Schellhorn as its new President and CEO. Schellhorn will also be joining the company’s Board of Directors.


Schellhorn joins GKC with a proven track record to spearhead the company's accelerated growth strategy to meet the demand for its lead product, the PKG™ system.

Please read the full press release here

Global Kinetics Corporation secures first US patent for its digital health system - 16 August 2017

GKC announced today it has received Notice of Allowance for a U.S. patent application, protecting the company's lead product, the PKG system.

The patent application pertains to the objective measurement of bradykinesia. Bradykinesia, or slowness of movement, is one of the most common symptoms, and a defining feature, of Parkinson's disease. The capacity to continuously measure this movement symptom underpins the PKG system.

The full press release can be accessed here

Evaluation of the Parkinson ’s KinetiGraph in monitoring and managing Parkinson ’s disease

While objective measurement is routine in clinical care of most conditions, this has not been the case for Parkinson's™ Disease. Recent innovations make objective measurement in Parkinson's™ Disease possible and its utility and how this should be assessed is discussed here.  Please read the full article here

GKC and Parkinson’s Foundation announce First Patient Enrolled in APPRISE Clinical Study - 31 May 2017

APPRISE is multi-center, randomized, controlled clinical study which assess the use of the Parkinson’s KinetiGraph™ (PKG™) system – called the Personal KinetiGraph in the US - for identifying patients who require a change to their clinical management plan, and the platform’s ability to help improve patient outcomes.

Please read the full press release here

GKC Big Data Highlights Unmet Needs & Global Variations in PD - 16 June 2017

Global Kinetics Corporation (GKC), today announced that it has developed a dataset of more than 10,000 reports of symptoms from patients with PD. The database was used to analyze symptomology from patients across the globe and presented in a poster at the recent International Congress of Parkinson’s Disease and Movement Disorders.

Please read the full press release here

GKC Present Data on its PKG™ at the 21st International Congress - 23 May 2017

Global Kinetics Corporation (GKC), a leader in digital health technology for people with Parkinson’s disease, today announced that four abstracts have been accepted to the 21st International Congress of Parkinson’s Disease and Movement Disorders, occurring June 4-8 in Vancouver, British Columbia. The studies presented involve the company’s proprietary Parkinson’s KinetiGraph™ (PKG™) technology – called the Personal KinetiGraph™ in the US.

To read more about the study and the collaboration, click here

Global Kinetics Corporation joins quest to predict Parkinson's - 31 January 2017

Global Kinetics Corporation is pleased to be working with neurologist and Parkinson's UK-funded researcher. Dr Alastair Noyce from the Institute of Neurology, University College London, to help spot early warning signs of Parkinson's.

To read more about the study and the collaboration, click here

CE mark secured for second generation PKG™ system - 4 January 2017

Global Kinetics Corporation, leader in digital health technology for people with Parkinson’s has secured CE marking on its new second generation Parkinson’s KinetiGraph™ (PKG™) system, indicating that the product complies with European health and safety requirements and legislation.

Please read the full press release here

uMotif technology partnership for Parkinson's trials - 16 December 2016

Global Kinetics Corporation and uMotif have announced a new partnership to offer a comprehensive, validated and simple to use data capture platform to advance the treatment and understanding of Parkinson’s disease.

Please read the full press release here

FDA clearance received for second generation PKG system - 22 September 2016

Global Kinetics Corporation, leader in health technology for people with Parkinson’s, today announced 510(k) marketing clearance for its next generation wrist-worn Parkinson’s KinetiGraph™ (PKG™) System from the US Food and Drug Administration.

Please read the full press release here

Global Kinetics Corporation announces new President and CEO - 30 August 2016

Leading Australian medical technology company Global Kinetics Corporation (GKC) is delighted to announce the appointment of US-based Timothy I. Still as its new President and CEO.

Please read the full press release here

National Parkinson Foundation collaborate on clinical research project - 23 June 2016

Global Kinetics Corporation, developer of the Personal KinetiGraph™ (PKG™) mobile health technology for the management of patients with Parkinson’s disease and other movement disorders, and the National Parkinson Foundation announced a clinical research collaboration to study the impact of continuous objective measurement of movement in patients with Parkinson’s disease using the PKG™ Movement Recording System.

Please read the full press release here

Parkinson's Institute to provide patients access to PKG™ - 15 January 2016

The Parkinson’s Institute and Clinical Center announces their partnership with Global Kinetics Corporation (GKC) in a pilot program that will provide Institute patients with access to an innovative mobile health technology. The Personal KinetiGraph™ (PKG™) is a wrist-worn device that offers comprehensive, automated reporting of a Parkinson’s patient’s movements so that neurologists and other physicians can objectively assess symptoms and response to medications.

Please read the full press release here

GKC closes Australia’s largest equity crowdfunding round - 27 June 2015

Through innovative crowdfunding platform OurCrowd, GKC has successfully raised $1.5M in capital, making this Australia’s largest equity crowdfunding round to-date. Following recent FDA clearance for the Parkinson’s KinetiGraph™, the money raised will be utilised by GKC to pursue commercialisation opportunities in the high-valued US market.

Please read the full press release here

Former Head of European Medicine Agency appointed to Board - 6 November 2014

GKC is delighted to announce that Dr Thomas Lonngren, Swedish regulatory affairs veteran and former Head of European Medicine Agency has been appointed to the GKC Board of Directors.

This appointment is part of an EU expansion agenda for GKC, which coincides with the granting of a key EU patent protecting the company’s ability to record, measure and assess clinical movement data in Parkinson’s patients using the proprietary PKG™ technology. It also secures proprietary mathematical algorithms associated with data analysis.

Please read the full press release here

USA market entry for PKG™ system - 11 September 2014

Australian technology company Global Kinetics Corporation has achieved a key milestone, securing important US regulatory clearance to market their world leading Parkinson’s disease mobile health technology in the high value American market.

Please read the full press release here